Based on pre-clinical findings and on more recent preliminary in vivo data it has been suggested that immunotherapy with Interleukin 2 (IL2) may be employed in the treatment of acute leukemia patients. Here we shall discuss the biological and clinical observations which indicate that this innovative therapeutic approach may play a role in the management of minimal residual disease.
Has IL2 a role in the management of minimal residual disease for acute leukemia? / Foa, Roberto; Meloni, Giovanna; Guarini, Anna; Mandelli, Franco; Gavosto, F.. - In: LEUKEMIA. - ISSN 0887-6924. - 6 SUPPL 4:(1992), pp. 92-94.
Scheda prodotto non validato
Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo
Titolo: | Has IL2 a role in the management of minimal residual disease for acute leukemia? | |
Autori: | ||
Data di pubblicazione: | 1992 | |
Rivista: | ||
Citazione: | Has IL2 a role in the management of minimal residual disease for acute leukemia? / Foa, Roberto; Meloni, Giovanna; Guarini, Anna; Mandelli, Franco; Gavosto, F.. - In: LEUKEMIA. - ISSN 0887-6924. - 6 SUPPL 4:(1992), pp. 92-94. | |
Handle: | http://hdl.handle.net/11573/422816 | |
Appartiene alla tipologia: | 01a Articolo in rivista |